Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q1 FY23 Earnings Presentation
16 slides from Aurobindo Pharma's earnings presentation, Aug 11, 2022
Slide 1: Cover letter to stock exchanges: Investor/Analysts Presentation
AURO BIND 0 August 11, 2022 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Phiroz Jeejeebhoy Towers, Sandra Kurla Complex, Sandra (E), 25 th floor, Dalal Street, MUMBAI ·400 051 MUMBAI ·400 001 Company Code No. AUROPH
Slide 2: Aurobindo Pharma Limited Earnings Presentation Q1FY23
Aurobindo Pharma Limited Earnings Presentation Q1FY23
Slide 3: Disclaimer
Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma Limited, nor shall it, or any par
Slide 4: Index
Index Page Q1FY23 Business & Financial Highlights 4 Financial Performance 9 Filings Snapshot 12 Aurobindo Pharma Limited | Earnings Presentation – Q1FY23 3
Slide 5: Q1FY23 Business & Financial Highlights
Q1FY23 Business & Financial Highlights 4
Slide 6: Quarterly Performance – Q1 FY23
Quarterly Performance – Q1 FY23 Revenue (Rs Crore) US Revenue ($ Mn) 6,236 5,942 6,002 5,809 5,702 401 364 367 363 386 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 EBITDA (Rs Crore) Net Debt to Equity* 1,209 1,187 0.00 1,016 -0.01 974 965 -0.07 -0.10 -0.11 Q1FY22 Q2FY22 Q3FY
Slide 7: Consolidated Financial & Business Highlights – Q1 FY23
Consolidated Financial & Business Highlights – Q1 FY23 Revenue from operations at Rs 6,235.9 crore, increased by 9.4% QoQ, US revenues at US$ 386 Million Research & Development (R&D) spend at Rs 310 crore in Q1FY23, 5% of revenue Vs. Rs. 358 crore in Q1FY22, 6.3% of revenue EBIDTA before Forex and O
Slide 8: US Business Performance Highlights
US Business Performance Highlights Revenue (Rs Crore) Revenue mix – Q1FY23 2,971 Orals 2,681 2,728 68.0% Total Injectables Injectables* 26.3% 18.6% Branded Oncology** Q1FY22 Q4FY22 Q1FY23 7.7% OTC 5.7% US Formulations • US revenue in Q1FY23 increased by 10.8% YoY and 8.9% on QoQ basis to Rs. 2,971 c
Slide 9: Europe, ARV, Growth Markets, API Business Revenues & Performance Highlights
Europe, ARV, Growth Markets, API Business Revenues & Performance Highlights In Rs Cr Europe Growth Markets ARV API 431 913 1,583 906 1,541 1,548 391 380 329 296 236 812 Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q4FY22 Q1FY23 • Europe revenue in Q1FY23 was • Revenue from G
Slide 10: Financial Performance
| _ Financial Performance ‘ AUROBINDO Committed to healthier life! 203 Windsor ‘Center Drive
Slide 11: Consolidated Profit & Loss Statement (as reported)
Consolidated Profit & Loss Statement (as reported) Rs Cr Q1FY23 Q1FY22 (%) Chg Q4FY22 (%) Chg Revenue from operations 6,235.9 5,702.0 9.4 5,809.4 7.3 Gross Profit 3,349.2 3,335.8 0.4 3,285.2 1.9 Gross Margin 53.7% 58.5% 56.5% Overheads 2,384.5 2,126.4 12.1 2,310.8 3.2 EBITDA (before forex and other
Slide 12: Debt profile
Debt profile Debt as on (Rs Cr) Mar-19 Mar-20 Mar-21 Mar-22 Jun-22 Fx Loan US$ Mn Closing Rate1 US$ = INR 69.15 75.66 73.11 75.79 78.97 1007 732 674 313 277 Fx Loan restated in INR 6,959.0 5,549.2 4.928.8 2,222.7 2,190.6 Rupee Loan 8.1 16.9 43.6 150.1 0.0 Gross Debt 6,967.1 5,566.1 4,972.4 2,372.8 2
Slide 13: Filing Status
§ AUROBINDO Committed to healthier life! 203 Windsor ‘Center Drive
Slide 14: US Filings Snapshot as on 30th Jun 2022
US Filings Snapshot as on 30th Jun 2022 ANDA Filings Aurobindo (Excl. Eugia Pharma Addressable Eugia Pharma Specialty Group 516 Therapy ANDAs Market Size 383 133 (US$ Bn) Specialty Group) CNS 135 27.47 190 71 154 CVS 106 36.31 35 ARV** 39 0.87 Final Tentative Under Gastroenterological 39 3.57 Approv
Slide 15: Global regulatory filing details
Global regulatory filing details As at As at As at As at As at As at As at As at Category Approvals Mar 16 Mar 17 Mar 18 Mar 19 Mar 20 Mar 21 Mar 22 Jun 22 Formulations US* 398 429 478 541 586 639 727 741 551 (FA: 516, TA:35) 2,945 Dossiers (357 Europe** 2,224 2,521 2,848 3,003 3,214 3,374 3580 3,63
Slide 16: Thank You
Thank You For more information, contact Investor Relations | Corporate Communications +91 40 6672 5067 ir@aurobindo.com www.aurobindo.com